A Pilot Study of Pembrolizumab and Single Agent Chemotherapy as First Line Treatment for Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer With Eastern Cooperative Oncology Group (ECOG) Performance Status of 2
University of Rochester
Summary
The purpose of this study is to understand if treatment with one chemotherapy medication combined with immune therapy (pembrolizumab) is tolerable and effective for patients with lung cancer and performance status of 2 (PS2), which means you have limitations in carrying out certain activities or spend up to half of your day resting.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: 1. Participants must be \>18 years old at time of diagnosis 2. Histologically confirmed non-small cell lung cancer 3. ECOG PS 2 4. Clinical staging of IIIc or IV disease. 4A. For patients with stage IIIc disease, patients are ineligible for or refuse standard treatment with platinum-double chemotherapy and radiation. 4B. For patients with stage IV disease, platinum doublet chemotherapy is not appropriate, deemed unsafe by the treating physician, or declined by the patient 4C. Screening lab work must meet the following parameters: 4Ca. Absolute neutrophil count (ANC) ≥1…
Interventions
- DrugPembrolizumab
Pembrolizumab 200 mg
- OtherPemetrexed (Chemotherapy)
500 mg/m2 day 1 of 21 day cycle (for non-squamous only)
- OtherNab-paclitaxel (Chemotherapy)
100 mg/m2 days 1,8 of 21 day cycle x 4 cycles
Locations (2)
- University of RochesterRochester, New York
- University of RochesterRochester, New York